Belapectin Shows Statistically Significant Efficacy in Advanced MASH Cirrhosis, Reducing Varices and Liver Stiffness
GALT has more than doubled off its 52-week low of $1.22 on elevated volume (2.8× avg).
Summary
Galectin Therapeutics presented new, positive analyses for its lead drug belapectin at the EASL 2026 conference, demonstrating statistically significant efficacy in advanced MASH cirrhosis. The data showed belapectin reduced new varices and liver stiffness, and improved markers of fibrogenesis. This is a critical positive development, especially following previous reports of "mixed outcomes" for the lead drug and the company's ongoing liquidity challenges, including a recent $200 million shelf registration. With no approved therapies for preventing varices or treating portal hypertension in MASH cirrhosis, these results highlight belapectin's potential to address a significant unmet medical need and could materially improve the company's outlook.
At the time of this announcement, GALT was trading at $2.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $183.7M. The 52-week trading range was $1.22 to $7.13. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.